hydroxychloroquine has been researched along with Ventricular Fibrillation in 4 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The incidence and nature of arrhythmias in the setting of COVID-19 were poorly documented across studies." | 2.72 | Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. ( Amarasekera, AT; Kayes, T; Kodsi, M; MacIntyre, CR; Malaty, M; Tan, TC, 2021) |
| "A ventricular fibrillation was treated with external cardiac massage." | 1.34 | [Treatment of hydroxychloroquine poisoning with extracorporeal circulation]. ( Blin, D; Derderian, F; Durand, M; Gonthier, YT; Mongenot, F, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jacquet-Lagrèze, M | 1 |
| Riad, Z | 1 |
| Hugon-Vallet, E | 1 |
| Ferraris, A | 1 |
| Fellahi, JL | 1 |
| Malaty, M | 1 |
| Kayes, T | 1 |
| Amarasekera, AT | 1 |
| Kodsi, M | 1 |
| MacIntyre, CR | 1 |
| Tan, TC | 1 |
| Jiménez-Jáimez, J | 1 |
| Macías-Ruiz, R | 1 |
| Bermúdez-Jiménez, F | 1 |
| Rubini-Costa, R | 1 |
| Ramírez-Taboada, J | 1 |
| Flores, PIG | 1 |
| Gallo-Padilla, L | 1 |
| García, JDM | 1 |
| García, CM | 1 |
| Suárez, SM | 1 |
| Molina, CF | 1 |
| López, MÁ | 1 |
| Tercedor, L | 1 |
| Mongenot, F | 1 |
| Gonthier, YT | 1 |
| Derderian, F | 1 |
| Durand, M | 1 |
| Blin, D | 1 |
2 reviews available for hydroxychloroquine and Ventricular Fibrillation
| Article | Year |
|---|---|
Left ventricular dysfunction in COVID-19: A diagnostic issue.
Topics: Azithromycin; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Cytokine Release Syndro | 2020 |
Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Atrial Fibrillat | 2021 |
2 other studies available for hydroxychloroquine and Ventricular Fibrillation
| Article | Year |
|---|---|
Absence of relevant QT interval prolongation in not critically ill COVID-19 patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin | 2020 |
[Treatment of hydroxychloroquine poisoning with extracorporeal circulation].
Topics: Adult; Antidotes; Bromazepam; Charcoal; Coma; Combined Modality Therapy; Diazepam; Drug Overdose; Ep | 2007 |